Inherited haemoglobin disorders, including thalassaemia and sickle-cell disease, are the
most common monogenic diseases worldwide. Several clinical forms of α-thalassaemia and …

The complex pathophysiology in β-thalassemia can translate to multiple morbidities that
affect every organ system. Improved survival due to advances in management means that …

This aim of this statement is to report an expert consensus on the diagnosis and treatment of
cardiac dysfunction in β-thalassemia major (TM). This consensus statement does not cover …

Background Oral deferiprone was suggested to be more effective than subcutaneous
desferrioxamine for removing heart iron. Oral once-daily chelator deferasirox has recently …

We present results from a prospective, multicenter, open-label, single-arm study evaluating
response of cardiac and liver iron to deferasirox therapy for 18 months. Twenty-eight …

Purpose The main purpose of this meta-analysis was to evaluate the impact of beta-
thalassemia major (BTM) on the health-related quality of life as assessed by the medical …

Background Thalassaemia is a hereditary anaemia due to ineffective erythropoiesis. In
particular, people with thalassaemia major develop secondary iron overload resulting from …

Deferasirox (DFX) monotherapy is effective for reducing myocardial and liver iron
concentrations (LIC), although some patients may require intensive chelation for a limited …

Combined chelation treatment may be a better approach for transfusion-dependent
thalassemia major patients with iron overload complications because of increased efficacy …

Accumulation of myocardial iron is the cause of heart failure and early death in most
transfused thalassemia major patients. T2* cardiovascular magnetic resonance provides …